Tech Company Financing Transactions
4D Molecular Therapeutics Funding Round
4D Molecular Therapeutics closed a $75 million Series C funding round on 6/17/2020. Investors included Viking Global Investors, Amzak Health Investors and ArrowMark Partners.
Transaction Overview
Company Name
Announced On
6/17/2020
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series C
Investors
Proceeds Purpose
The proceeds from this financing will be used to advance three of 4DMT's precision-guided AAV gene therapy product candidates through initial clinical proof-of-concept in patients, to advance 4DMT's proprietary product pipeline and next-generation Therapeutic Vector Evolution platform and to expand its internal GMP manufacturing capabilities.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
5858 Horton St. 455
Emeryville, CA 94608
USA
Emeryville, CA 94608
USA
Phone
Email Address
Overview
4D Molecular Therapeutics (Nasdaq: FDMT) designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Kirn
Chief Financial Officer
August Moretti
Chief Operating Officer
Theresa Janke
Chief Scientific Officer
Peter Francis
Chief Technical Officer
Fred Kamal
VP - Human Resources
Jessica Wilan
Browse more venture capital transactions:
Prev: 6/17/2020: Abacus Insights venture capital transaction
Next: 6/17/2020: Drishti venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs